Al's Comment:

This is a new way of delivery radiation to the tumor using nanoliposomes and Rhenium-186. Visit their website https://www.plustherapeutics.com/ to see how it works.  This phase 1 trial had impressive results: It was a dose finding trial. Those at the highest dose did not have any dose limiting toxcicities and 7 of 13 recurrent glioblastoma patients are still alive at an average of 453 days. This compares very favorably to history which tells us these patients live about 6  months (183 days). The trial for recurrent glioblastoma is still open, and they will soon start trials for pediatric brain tumors and leptomeningeal metastases.

 


Posted on: 11/22/2021

Plus Therapeutics Announces Positive Interim Data from ReSPECT-GBM Phase 1 Clinical Trial at the 2021 Society for Neuro-Oncology Annual Meeting

 


Click HERE to return to brain tumor news headlines.


Our privacy / cookie policy has changed.
Click
HERE to read it!